ABOUT

Molquant, Inc.

Boston-based Molquant builds tools to decipher the vast amount of information in the human genome. Using biologically-directed statistical approaches, Molquant tools reveal inherent relationships among functionally-related genes. Molquant tools solve challenging issues in genome-based genotype-to-phenotype correlation:

  • Linking genes to biology, pathways, tissues, diseases

  • Drug target evaluation and assessment

  • Biomarker generation and optimization

  • Biological annotation of unknown or uncharacterized genes

  • Reducing complexity of high-dimensionality data 

  • Quantitative trait assessment for polygenic phenotypes

Molquant provides a novel framework for quantifying genotype-to-phenotype associations. 

Murray Robinson, Ph.D.
Founder 

With more than 20 years experience exploring the molecular genetics of cancer to drive drug discovery and development, molecular biologist Dr. Robinson is a pioneer in the effort to decode our genes.  First at Amgen Inc., then at AVEO Pharmaceuticals, Murray and his teams discovered cancer genes and pathways, moved a half dozen drugs into the clinic, and developed innovative bioinformatics approaches to match drugs with appropriate clinical settings.  His experience and expertise in cancer, diseases defined by genetic changes, as well as a personal connection to genetics has recently led Murray to develop tools for interpreting the functions of genes in the broader field of genomics. Murray received his bachelors degree at the University of California at San Diego and his PhD at the California Institute of Technology.

Recent Work:
ASCO GU 2013 Abstract 361 Poster Presentation "Tivozanib TIVO-1 Hypoxia Signature ccRCC" 
Pharma Strategy Blog Feb. 25, 2013 "Will Biomarkers Revolutionize Treatment with Tivozanib?"
Genetic Engineering News (GEN) Oct. 1, 2012 "Animal Models Get Closer to Mimicking Humans"
Current Oncology News Oct. 2011 "Development of Second-Generation VEGFR Tyrosine Kinase inhibitors: Current Status"
Nature Biotechnology Jan. 2010 "Chimeric Mouse Tumor Models Reveal Differences In Pathway Activation Between ERBB Family- and KRAS-dependent Lung Adenocarcinomas"
Cell Cycle 2009 "Human-In-Mouse Breast Cancer Model"